Posts by: Alice Melão

News

Alkermes filed a request for the approval of diroximel fumarate (BIIB098) to treat relapsing forms of multiple sclerosis (MS) with the U.S. Food and Drug Administration (FDA). If ... Read more

December 12, 2018December 12, 2018

Ocrevus Now Available Through NHS Scotland to Treat RRMS

News

Ocrevus (ocrelizumab, by Genentech) is now available through the National Health System (NHS) of Scotland to treat patients with relapsing-remitting multiple sclerosis (RRMS). The decision by ... Read more

December 11, 2018December 11, 2018

WUSTL Team Receives $6.3 Million Grant to Develop PET Scan Tracers

News

The Washington University School of Medicine in St. Louis (WUSTL) will create a new research center to investigate and advance the development of tracers for positron emission ... Read more

November 30, 2018December 13, 2018

Gilenya Now Approved in Europe to Treat Children, Adolescents with RRMS

News

Gilenya (fingolimod) was approved by the European Commission as a treatment for children and adolescents, ages 10 to 17, with relapsing-remitting multiple sclerosis (RRMS), Novartis announced. ... Read more

November 28, 2018December 4, 2018

Artificial Intelligence May Help Reduce Dosage of Gadolinium in MRIs, Researchers Suggest

News

Artificial intelligence can help reduce the amount of gadolinium used as a contrast agent in MRI (magnetic resonance imaging) scans, preventing the agent’s potential toxicity when ... Read more

November 21, 2018November 21, 2018

Phase 2 Trial of NurOwn Stem Cell Therapy in Progressive MS Planned for US, BrainStorm Announces

News

BrainStorm Cell Therapeutics is planning to launch a Phase 2 clinical trial in the United States to evaluate the safety and activity of its lead cell ... Read more

November 20, 2018November 28, 2018

FDA Approves Generic Version of Aubagio to Treat Relapsing MS, Glenmark Pharma Says

News

The U.S. Food and Drug Administration (FDA) has approved a generic version of Aubagio (teriflunomide) tablets at the 7 mg and 14 mg doses marketed by Sanofi, ... Read more

November 1, 2018November 6, 2018

Protein Produced by Common Gut Bacteria Can Trigger Autoimmunity, Study Suggests

News

Bacteria that reside in human gut may trigger autoimmune reactions by producing human-like proteins that mimic a naturally occurring and crucial cell protein. Researchers at Queen’s ... Read more

October 29, 2018October 29, 2018

Mavenclad Named ‘Rapid Uptake Product’ in UK with Goal of Speeding Its Availability in NHS

News

Mavenclad (cladribine tablets, 10 mg) was one of the seven medicinal and medical technology products selected by the Accelerated Access Collaborative (AAC) as a “rapid uptake ... Read more

October 25, 2018October 31, 2018

Stem Cells from MS, Parkinson’s Patients Voyaging to Space Station to Study Disease Impact on Brain in Microgravity

News

Stem cells from patients with Parkinson’s disease and primary progressive multiple sclerosis (PPMS) are soon to voyage into space, and be brought aboard the International Space Station so ... Read more

October 19, 2018October 23, 2018

Enzyme Produced by Gut Bacteria Linked to T-cell Attacks on Myelin in Study

News

An enzyme produced by bacteria in the gut was seen to activate immune cells linked to the development and progression of multiple sclerosis, a finding that may pave ... Read more

October 18, 2018October 25, 2018

#ECTRIMS2018 – Role of Brain Atrophy in MS Progression Poorly Understood by Patients, MSAA Survey Finds

News

Although brain atrophy — the loss of brain volume — is an increasingly important measure in multiple sclerosis trials and treatment outcomes, MS patients have a ... Read more

October 15, 2018October 15, 2018

#ECTRIMS2018 – Additional Analysis on Ozanimod Demonstrate Its Potential to Treat Relapsing MS

News

Additional analysis of clinical data from Celgene’s investigational agent ozanimod continues to demonstrate its potential to benefit patients with relapsing multiple sclerosis (MS). Findings from the ... Read more

October 12, 2018October 12, 2018

#ECTRIMS2018 – MS Patients More Prone to Health Problems Before, After Diagnosis, Study Suggests

News

Patients with multiple sclerosis (MS) are more likely to experience health problems before they receive their formal diagnosis, as well as to experience serious non-MS-related complications ... Read more

October 10, 2018October 10, 2018

#ECTRIMS2018 — Merck KGaA to Present Latest Data on MS Portfolio

News

Merck KGaA will present the latest advances made on several of its therapies aiming to treat multiple sclerosis (MS) at the 34th Congress of the European ... Read more

October 10, 2018October 17, 2018

FDA, EMA Agree to Review Novartis Therapy Siponimod to Treat SPMS

News

Novartis is seeking U.S. and European approval of its investigational oral agent siponimod to treat adults with secondary progressive multiple sclerosis (SPMS). The U.S. Food and Drug ... Read more

October 8, 2018October 8, 2018

UVA Scientist Awarded $5.6M by NIH to Further Study Lymph System and Brain Connection

News

Jonathan Kipnis, the researcher who discovered that lymphatic vessels are important mediators of the underlying molecular mechanism of multiple sclerosis (MS), has received the prestigious Director’s ... Read more

September 26, 2018September 26, 2018

Nyrada Identifies Novel IRAK4 Inhibitors that May Prevent Neuroinflammation

News

Nyrada, a subsidiary company of Noxopharm, discovered a set of novel compounds that can cross the blood-brain barrier and blood-nerve barriers, and inhibit a master regulator ... Read more

September 21, 2018September 26, 2018

Ocrevus Climbing as First-line DMT for RRMS Among Neurologists Surveyed in Spherix Report

News

Eighteen months after its entrance into the U.S. market, Genentech’s Ocrevus (ocrelizumab) has become the monoclonal antibody of choice to treat patients with multiple sclerosis (MS), according ... Read more

September 5, 2018September 5, 2018

Mavenclad Approved to Treat Highly Active Relapsing MS Patients in Ireland

News

Adults in Ireland with highly active relapsing multiple sclerosis (MS) now can be treated with Mavenclad (cladribine tablets, 10 mg), the first short-course oral treatment approved ... Read more

August 8, 2018August 8, 2018

Quanterix’s Simoa Assay May Make Neurofilament Light Chain Useful Blood Biomarker of MS and Its Likely Progression

News

Quanterix’s ultra-sensitive Simoa assay has the potential to open new uses for the brain biomarker known as neurofilament light chain, including the possibility to detect early ... Read more

August 2, 2018August 7, 2018

Potential B-cell Targeting Oral MS Treatment, PRN2246, Shows Ability to Reach Brain in Phase 1 Study

News

Results from a first-in-human study assessing the safety and early activity of PRN2246 confirmed that the oral compound can reach into the brain and spinal cord. This ... Read more

July 31, 2018July 31, 2018

FDA to Review EMD Serono’s New Request for Approval of Cladribine for Treating Relapsing MS

News

Seven years after it first denied the request, the U.S. Food and Drug Administration accepted for review EMD Serono’s resubmitted New Drug Application (NDA) for cladribine ... Read more

July 27, 2018July 30, 2018

Oral DMTs Still Common 1st Therapy for New MS Patients but Ocrevus Having Impact, Market Report Says

News

Oral disease-modifying therapies (DMTs) are the most common first choice of treatment for people newly diagnosed with multiple sclerosis (MS) in the United States, an analysis ... Read more

July 24, 2018July 25, 2018

Enzyme Key to Myelin Renewal and Nerve Cell Health Possibly Identified in Study

News

A better understanding of the processes behind a continual and healthy renewal of myelin — the fatty, protective substance wrapping nerve cell fibers — may now ... Read more

July 17, 2018July 17, 2018

Progressive MS Patients with Considerable Disability Ably Treated with Cladribine, UK Case Study Reports

News

Cladridine may be effective in preventing disability progression and reducing damage to nerve cells in people with progressive forms of multiple sclerosis (MS), researchers suggest based on a ... Read more

July 13, 2018July 17, 2018

Common Anti-Parasitic Agent Eases Motor Symptoms, Aids Remyelination in MS Mouse Model

News

A common anti-parasitic agent showed a potential to prevent inflammation and to promote nerve cell recovery — remyelination — in a mouse model of multiple sclerosis ... Read more

July 3, 2018

No Risk of MS Found in GlaxoSmithKline Vaccine for Swine Flu, Canadian Study Says

News

Protecting the public against an outbreak like the swine flu using GlaxoSmithKline‘s vaccine Arepanrix — or a similar vaccine with an AS03 adjuvant delivery system — does not increase a ... Read more

June 28, 2018June 28, 2018

Probe That Acts as PET Scan Tracer May Give Glimpse into Gene Therapy’s Effects on Brain

News

A radioactive probe that might enable imaging tools to effectively monitor what a gene therapy is doing in the brain — important in treating diseases like ... Read more

June 21, 2018June 21, 2018

#EAN2018 – Pupil Response to Light Linked to RRMS Duration and Severity in Study

News

Measuring the response of the pupil to light stimulating the eye is a non-invasive and easy way to assess multiple sclerosis (MS) severity and progression, researchers ... Read more

June 20, 2018June 27, 2018

#EAN2018 – New Guidelines for MS Treatment in Europe Set by EAN, ECTRIMS

News

New treatment guidelines for multiple sclerosis (MS) patients in Europe were set in place through an initiative undertaken by the European Academy of Neurology (EAN) and ... Read more

June 19, 2018June 19, 2018

#EAN2018 – Ocrevus Lowers Relapse Rates Over Long Term and Better Than Rebif Does, Data Show

News

Long-term treatment with Ocrevus (ocrelizumab) — as well as switching from Rebif (interferon beta-1a) to Ocrevus — leads to a significant and sustained reduction in disease ... Read more

June 15, 2018June 21, 2018

#EAN2018 – Ocrevus May Delay Progression to Wheelchair by Up to 7 Years, New Analysis of PPMS Patient Data Shows

News

Treatment with Ocrevus (ocrelizumab) slows disability progression in primary progressive multiple sclerosis (PPMS) in ways that may be of considerable importance to patients — including the ... Read more

June 8, 2018June 8, 2018

Mobility Devices for People Who Have Lower-Limb Paralysis are Flawed, Online Survey Reveals

News

More investment and new technological developments are needed to assist people who have limited mobility because of lower-limb paralysis. That was the major conclusion of an ... Read more

June 7, 2018June 8, 2018

#CMSC2018 – Pharmacist Discusses Advances, Challenges in Cannabinoids Research to Treat MS

News

Several studies have demonstrated the therapeutic potential of cannabis and its derivate products to manage the symptoms of multiple sclerosis (MS) and other neurodegenerative diseases. But ... Read more

June 5, 2018June 5, 2018

#CMSC2018 — Advances Made in Care of Children with MS, but Challenges Remain, Expert Says

News

While the treatment and care of children and teenagers with multiple sclerosis (MS) has seen many developments in recent years, there are still many challenges to ... Read more

May 25, 2018May 30, 2018

Limited Use of Large Muscles Affects Health of Nerve Cell-producing Stem Cells in Brain, Mouse Study Finds

News

Lesser time spent exercising and using large muscles can result in serious alterations in the metabolism of brain stem cells and their ability to generate new nerve ... Read more

May 15, 2018May 15, 2018

Gilenya Approved by FDA as First DMT for Children, Ages 10 and Older, with Relapsing MS

News

Gilenya (fingolimod) has become the first disease-modifying therapy approved by the U.S. Food and Drug Administration (FDA) to treat children and adolescents with relapsing forms of ... Read more

May 8, 2018May 8, 2018

Rituximab Seen to Ably and Safely Treat Refractory RRMS Patients in French Study

News

An approved lymphoma treatment, rituximab was found to be effective and safe for relapsing-remitting multiple sclerosis (RRMS) patients whose active disease has failed to respond to immunosuppressive ... Read more

May 3, 2018May 3, 2018

Mavenclad Effective in Treating Highly Active MS, New CLARITY Analysis Shows

News

An additional analysis of data from the CLARITY study confirmed the long-term benefits of treatment with Mavenclad (cladribine tablets) for patients with highly active relapsing forms ... Read more

Pin It on Pinterest